Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.286 SEK | +3.62% | +34.91% | -97.14% |
May. 22 | Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? | CI |
May. 16 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.14% | 39.78M | |
+52.78% | 63.85B | |
-1.85% | 41.83B | |
+40.29% | 40.47B | |
-10.02% | 27.17B | |
+13.98% | 26.52B | |
-20.41% | 18.69B | |
+3.35% | 12.73B | |
+21.90% | 12.11B | |
+28.95% | 12.07B |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Transcript : Xbrane Biopharma AB, Nine Months 2022 Earnings Call, Oct 28, 2022